MCF2L

Across TCGA pan-cancer cohorts, MCF2L RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MCF2L data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher MCF2L RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MCF2L expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

ACC, UCEC, and HNSC are the cancer types where MCF2L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.285	0.611	<.001	104	view →
UCEC	DFS	Tertile	All	0.925	0.836	.002	70	view →
HNSC	DFS	Tertile	IV	0.799	0.543	<.001	70	view →
KIRC	OS	Median	All	0.854	0.755	<.001	67	view →
BLCA	OS	Median	All	0.774	0.645	<.001	67	view →
MESO	OS	Median	All	0.265	0.501	<.001	53	view →
PAAD	OS	Median	All	0.697	0.518	.001	52	view →
KIRP	OS	Tertile	All	0.917	0.805	.008	37	view →
UCS	DFS	Median	IV	0.909	0.416	.008	30	view →
COAD	OS	Quartile	All	0.692	0.892	.004	21	view →
THCA	DFS	Median	All	0.892	0.773	.002	15	view →
LAML	DFS	Median	All	0.469	0.286	.025	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MCF2L–ACC (DFS)

Open the ACC breakdown →